Aplasia cutis congenita in surviving co-twin after propylthiouracil exposure in utero

Löllgen, Ruth M; Calza, Anne-Marie; Schwitzgebel Luscher, Valérie; Pfister, Riccardo

doi:10.1515/jpem.2011.099

Scientific article

English

Aplasia cutis congenita in surviving co-twin after propylthiouracil exposure in utero

ContributorsLöllgen, Ruth M; Calza, Anne-Marie; Schwitzgebel Luscher, Valérie; Pfister, Riccardo

Published inJournal of pediatric endocrinology & metabolism, vol. 24, no. 3-4, p. 215-218

Publication date2011

Abstract

Aplasia cutis congenita (ACC) has been observed after fetal exposure to the antithyroid drug methimazole (MMI), but not reported after propylthiouracil (PTU), the current antithyroid drug of choice during pregnancy. This occurrence has implications for patient information and causal research.

Keywords

Abnormalities, Drug-Induced/etiology/pathology
Antithyroid Agents/adverse effects
Diseases in Twins/etiology/pathology
Ectodermal Dysplasia/etiology/pathology
Female
Gestational Age
Graves Disease/complications/diagnosis/drug therapy
Humans
Infant, Newborn
Maternal Exposure
Pregnancy
Pregnancy Complications/diagnosis/drug therapy
Propylthiouracil/adverse effects

Affiliation entities

Research groups

Citation (ISO format)

LÖLLGEN, Ruth M et al. Aplasia cutis congenita in surviving co-twin after propylthiouracil exposure in utero. In: Journal of pediatric endocrinology & metabolism, 2011, vol. 24, n° 3-4, p. 215–218. doi: 10.1515/jpem.2011.099

Article (Published version)

Identifiers

PID : unige:25760
DOI : 10.1515/jpem.2011.099
PMID : 21648296

Journal ISSN0334-018X

531views

0downloads

Creation17/12/2012 16:49:00

First validation17/12/2012 16:49:00

Update time14/03/2023 20:58:45

Status update14/03/2023 20:58:45

Last indexation30/10/2024 09:33:32

Archive ouverte UNIGE

Aplasia cutis congenita in surviving co-twin after propylthiouracil exposure in utero

Aplasia cutis congenita (ACC) has been observed after fetal exposure to the antithyroid drug methimazole (MMI), but not reported after propylthiouracil (PTU), the current antithyroid drug of choice during pregnancy. This occurrence has implications for patient information and causal research.

Technical informations